Clay Siegall is the famed founder and celebrated CEO of Seattle Genetics, a leading biotech firm that specializes in developing targeted therapy drugs for diseases that have not shown any significant improvement over the decades. Clay has led the firm towards prosperity since its inception in 1998. He has developed a robust pipeline of over 20 drugs and partnerships with renowned drug manufacturers like Bayer and Pfizer. Clay has grown Seattle Genetics to an authentic power player in the cancer research platform. Moreover, he believes that the old cancer treatment procedure should be replaced with more tolerable and effective targeted drugs.
A Closer Focus on Seattle Genetics
Clay Siegall gave two reasons for founding Seattle Genetics when Inspirery interviewed him. Clay revealed that he was interested in medicine, the power of technology, and the reason to overcome diseases. He was also interested in cancer treatment when he was pursuing zoology at the University of Maryland. Clay realized that cancer treatments like amputation and radical surgery had better treatment options.
Clay mentioned that Seattle Genetics made money from selling its proprietary drugs like ADC, which was approved by Food and Drug Administration. He also revealed that the company became profitable around ten years after the initial public offering (IPO). Clay cited that Seattle Genetics was affected during the depletion phase of the company’s operation capital in 1999 to 2000. He revealed that he overcame that scenario by working through the company’s financial threats. Additionally, Clay confirmed that he was currently successful because of hard work.
Clay Siegall has been the esteemed president and talented CEO of Seattle Genetics since 1998. He serves as the Chairman of the Board of Directors of Seattle Genetics. Clay’s leadership has enabled the company to build a diverse pipeline of antibody-based cancer therapies, for instance, ADCETRIS (brentuximab vedotin) that was accredited by the U.S. FDA in 2011.
Previously, Clay worked at National Cancer, National Institute of Health from 1988 to 1991. He later resigned to join Bristol-Myers Squibb Pharmaceutical Research Institute. Clay exited from the company, in 1997, to co-found Seattle Genetics.
Clay serves on the Boards of Director of Alder BioPharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical. Clay pursued a B.S in Zoology from the renowned University of Maryland. He also went to study at George Washington University where he acquired a Ph.D. in Genetics.